Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience

Upfront docetaxel or novel hormonal agents (NHA) such as abiraterone and enzalutamide have become the standard of care for metastatic hormone sensitive prostate cancer (mHSPC). We evaluated real-world management of patients treated with these agents at a single center. We identified 94 de novo mHSPC...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2022-08, Vol.17 (8), p.e0264800-e0264800
Hauptverfasser:	Guin, Sunny, Liaw, Bobby K, Jun, Tomi, Ayers, Kristin, Patel, Bonny, O'Connell, Timmy, Deitz, Matthew, Klein, Michael, Mullaney, Tommy, Prentice, Tony, Newman, Scott, Fink, Marc, Zhou, Xiang, Schadt, Eric E, Chen, Rong, Oh, William K
Format:	Artikel
Sprache:	eng
Schlagworte:	Automation Biology and Life Sciences Cancer therapies Clinical trials Complications and side effects Data warehouses Diagnosis Evaluation Hazard assessment Hospitals Information retrieval Medical diagnosis Medicine and Health Sciences Metastases Metastasis Patients Prostate cancer Statistical analysis Statistical models Survival Survival analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!